A NOVEL MTORC2-AKT-ROS AXIS TRIGGERS MITOFISSION and MITOPHAGY-ASSOCIATED EXECUTION of COLORECTAL CANCER CELLS UPON DRUG-INDUCED ACTIVATION of MUTANT KRAS-Reference-Cited by-同舟云学术

A NOVEL MTORC2-AKT-ROS AXIS TRIGGERS MITOFISSION and MITOPHAGY-ASSOCIATED EXECUTION of COLORECTAL CANCER CELLS UPON DRUG-INDUCED ACTIVATION of MUTANT KRAS

Published:2024-01-23 Issue: Volume: Page:
ISSN:1554-8627
Container-title:Autophagy
language:en
Short-container-title:Autophagy

Author:

Iskandar Kartini¹,Foo Jonathan¹²,Liew Angeline Qiu Xia¹²,Zhu Haiyuxin¹,Raman Deepika¹,Hirpara Jayshree L.³,Leong Yan Yi¹,Babak Maria V.⁴,Kirsanova Anna A.⁴,Armand Anne-Sophie⁵,Oury Franck⁵,Bellot Gregory¹,Pervaiz Shazib¹²⁶⁷⁸^ORCID

Affiliation:

1. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

2. Integrative Science and Engineering Programme (ISEP), NUS Graduate School (NUSGS), National University of Singapore, Singapore

3. Cancer Science Institute, National University of Singapore, Singapore

4. Drug Discovery Laboratory, Department of Chemistry, City University of Hong Kong, Hong Kong, SAR, China

5. Institut Necker Enfants Malades (INEM), INSERM U1151, Université Paris Cité, Paris, France

6. NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore

7. NUS Medicine Healthy Longevity Program, National University of Singapore, Singapore

8. National University Cancer Institute, National University Health System, Singapore

Funder

National Medical Research Council, Singapore

Publisher

Informa UK Limited

Subject

Cell Biology,Molecular Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/15548627.2024.2307224

Reference64 articles.

1. The Frequency of Ras Mutations in Cancer

2. RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally;Miller MS;Front Genet,2011

3. Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo;Sakamoto K;Scientific Reports,2020

4. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors;Hong DS;New England Journal of Medicine,2020

5. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/Metastatic Non Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation;Jänne PA;European Journal of Cancer,2020